NXTAR, RNA molecule suppresses prostate tumor growth
A study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate tumors. According to the research — restoring this so-called long noncoding RNA, NXTAR, could be a new strategy to treat prostate cancer that has developed resistance to hormonal therapies.
Researchers identify inhibitor that overcomes drug resistance in prostate cancer AR protein production in the presence of enzalutamide through ACK1-mediated histone phosphorylation is a new finding. The new inhibitor, (R)-9b, that the research team has developed could become a new therapeutic modality, especially for those patients not responsive to enzalutamide or have developed resistance to it. The compound will be in clinical trials in 1-2 years.
NCI NIH 2012
Cancer cells have ‘hijacked’ histone modification mechanism to lower histone levels and thus activate the growth and survival of cancer cells. The research team discovered that a modified histone itself regulates histone synthesis. The modification is histone H2B phosphorylation (in this case the process of adding a phosphate to a protein molecule) at tyrosine 37 (tyrosine is one of the amino acids), which is critical for suppression of core histone mRNA synthesis.The significance of this process in cancer cells became evident when they identified a tyrosine kinase, WEE1, as being a critical regulator of the process.